Skip to main content

Year: 2022

With 4.2 % CAGR, Ophthalmic Devices Market Size worth USD 32.36 billion by 2027

According to Fortune Business Insights, the Global Ophthalmic Devices Market size is estimated to reach USD 32.36 Billion by 2027, mentions that the market stood at USD 25.04 billion in 2019 and is likely to exhibit a CAGR of 4.2 % between 2020 and 2027; Increasing Prevalence of Eye Disorders to Spur Demand Pune, India, Oct. 12, 2022 (GLOBE NEWSWIRE) — The global ophthalmic devices market size is expected to showcase an exponential growth by reaching USD 32.36 billion by 2027 while exhibiting a CAGR of 4.2% between 2020 and 2027. This is attributable to the increasing prevalence of eye disorders across the globe. Fortune Business Insights, in its latest report, titled, “Ophthalmic Devices Market Size, Share & COVID-19 Impact Analysis, By Surgical (Implants, Consumables, and Equipment) and Vision Care (Contact Lenses and Ocular...

Continue reading

With 25.4% CAGR, Customer Data Platform Market Worth USD 6.94 Billion by 2029

According to Fortune Business Insights, the global customer data platform market size is projected to reach USD 6.94 billion in 2029, at a CAGR of 25.4% during the forecast period, 2022-2029 Pune, India, Oct. 12, 2022 (GLOBE NEWSWIRE) — The global customer data platform market size is projected to grow from USD 1.42 billion in 2022 to USD 6.94 billion in 2029 at a CAGR of 25.4% in the forecast period. Fortune Business Insights™ published this information in its recent report, titled “Customer Data Platform Market Forecast, 2022-2029.” As per the report, the market size was USD 1.16 billion in 2021.Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/customer-data-platform-market-100633Key Industry Development January 2020 – Tealium, Inc. and Invoca Inc. announced a strategic partnership...

Continue reading

SCADA Market Size [2022-2029] | Industry Share, Revenue, Key Players, CAGR, Demand and Sales Forecast

Some of the key competitors in the SCADA market include Emerson Electric Co., Schneider Electric, ABB Ltd., AVEVA Group plc, Hitachi, Ltd., JFE Engineering Corporation, Check Point Software Technologies Ltd., Yokogawa Electric Corporation. Pune, India, Oct. 12, 2022 (GLOBE NEWSWIRE) — The SCADA market is expected to gain momentum from its increasing usage in a wide range of applications, such as telecom & IT, electric & gas utilities, and manufacturing for supervisory process management. Its full form is Supervisory Control and Data Acquisition. This information is given by Fortune Business Insights™ The report further mentions that the SCADA system consists of Human Machine Interface (HMI) software solution. It delivers direct interaction of the end-user with devices such as motors, sensors, valves, and pumps. The data...

Continue reading

Reconciliation Software Market Size [2022-2029] | Industry Share, Revenue, Key Players, CAGR, Demand and Sales Forecast

Companies Profiled in the Extended Reality Market are ReconArt, Inc., SmartStream Technologies ltd., BlackLine Inc., Trintech Inc., SAP SE, Fiserv, Inc., Aurum Solutions, Cashbook, Rimilia Holdings Ltd., OneStream Software LLC, Oracle Corporation Pune, India, Oct. 12, 2022 (GLOBE NEWSWIRE) — The increasing automation and optimization of reconciliation management is expected to aid the expansion of the market, states Fortune Business Insights, in a report, titled “Reconciliation Software Market size, share & industry analysis, By Component (Software, Services), By Deployment (Cloud, On-premise), By Application (Financial Services, Insurance, Retail, Real Estate, Government, Others) and regional forecast 2020-2027.” The increasing digitalization is expected to spur opportunities for the market. The coronavirus incident has...

Continue reading

With 5.9% CAGR, Artificial Tears Market Size to Surpass Around USD 4.30 Billion by 2027

According to Fortune Business Insights, Artificial Tears Market to Reach USD 4.30 Billion by 2027; Introduction of Systane’s Eye Drop Range to Bode Well for the Market Pune, India, Oct. 12, 2022 (GLOBE NEWSWIRE) — The global artificial tears market size is expected to capacity USD 4.30 billion by 2027, exhibiting a CAGR of 5.9% during the forecast period. The growing incidence of ocular diseases can be a vital factor amplifying the hike of the global market, the market size stood at USD 2.64 billion in 2019.Artificial tears are a type of medical device that are often used to treat eye diseases and injuries. They are made from a mixture of water and a type of artificial eye fluid, which is often made from a type of synthetic oil. They are often used to replace the natural tears that are produced in the eye.Request a Sample Copy...

Continue reading

Results for digital subscriptions of AS Ekspress Grupp in the 3rd quarter of 2022

The number of digital subscriptions of AS Ekspress Grupp increased by 21% in total in the Baltic States year-over-year and totalled 151 430 at the end of September.The number of digital subscriptions of AS Delfi Meedia that publishes the news portal Delfi, newspapers Eesti Päevaleht, Maaleht, Eesti Ekspress and several popular magazines increased by 7% year-over-year (3rd quarter: -7%, first 9 months: 4%) and totalled 77 920. The number of digital subscriptions of AS Õhtuleht Kirjastus, 50% of which is owned by Ekspress Grupp, increased by 23% year-over-year (3rd quarter: 6%, first 9 months: 12%) and totalled 23 548. The number of digital subscriptions of Geenius Meedia OÜ increased by 51% year-over-year (3rd quarter: 14%, first 9 months: 26%) and totalled 5 162. In Latvia, the number of digital subscriptions of Delfi A/S increased by...

Continue reading

Positive new data for Roche’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA)

New two-year Evrysdi data show improvement or maintenance of motor function in people with SMA, a progressive neuromuscular disease that can be fatal The JEWELFISH study enrolled the broadest and most diverse patient population ever studied in an SMA trial Longer-term safety data consistent with that previously seen in earlier trials and low study drop-out rate Evrysdi has proven efficacy in babies, children and adults, with more than 7,000 patients treated to date worldwideBasel, 12 October 2022- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new two-year data from the JEWELFISH study evaluating Evrysdi® (risdiplam) in people with Type 1, 2 or 3 SMA aged 6 months to 60 years at time of enrolment. Patients had been previously treated with other approved or investigational SMA-targeting therapies, including nusinersen (Spinraza(R))...

Continue reading

Unibail-Rodamco-Westfield launches in-house retail media agency, Westfield Rise

Paris, Amsterdam, October 12, 2022 Press Release Unibail-Rodamco-Westfield launches in-house retail media agency, Westfield Rise Unibail-Rodamco-Westfield (URW), the developer and operator of Flagship retail and lifestyle destinations, announces the launch of Westfield Rise, an in-house media, brand experience and data partnerships agency. The agency will serve as a one-stop-shop for brands and media-buyers to create innovative and measurable campaigns across URW’s platform of best-in-class retail media assets at its 57 shopping malls in Europe – including its network of 1,700 digital billboards, one of the largest on the continent, 170 brand experience locations, and its range of online advertising capabilities. Caroline Puechoultres, Chief Customer Officer, Unibail-Rodamco-Westfield, said: “With the launch of Westfield Rise, we will...

Continue reading

Philips provides update on its financial performance in Q3 2022

October 12, 2022 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today provided an update on its third-quarter 2022 financial results and full-year outlook. The company will report the final results on October 24, 2022. Group sales and profitabilityPhilips’ financial performance in the third quarter was largely impacted by continued supply chain challenges that were more significant than anticipated in the quarter, impacting deliveries and customer installations. As a result, sales for the Group are expected to be approximately EUR 4.3 billion with a comparable sales decline of approximately 5%. Philips’ Diagnosis & Treatment businesses are expected to show a low-single-digit comparable sales decline and the Connected Care businesses a mid-teen decline, while the Personal Health...

Continue reading

Roche to introduce its next-generation portfolio of SARS-CoV-2 rapid antigen tests (“2.0”) under CE Mark for self-test and professional use

Broad and trusted portfolio of COVID-19 rapid tests feature innovative updates and enhanced performance, building on insights gained throughout the pandemic All tests now work seamlessly with navify® Pass, Roche’s digital solution that allows individuals and healthcare professionals to immediately store, display, and share COVID-19 vaccination status and test results through a unique data matrix Roche maintains the capacity to provide tens of millions tests each month to meet sustained high worldwide demand from individuals and healthcare professionalsBasel, 12 October 2022- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of its next-generation portfolio SARS-CoV-2 rapid antigen tests (“2.0”) for self-testing and professional use in countries accepting the CE Mark. Distribution of the new rapid test portfolio is projected...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.